Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M1774 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dosing Regimen 1 (Phase 1b): M1774 + Cemiplimab | EXPERIMENTAL | - |
| Dosing Regimen 2 (Phase 1b): M1774 + Cemiplimab | EXPERIMENTAL | - |
| Stratum A (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b | EXPERIMENTAL | - |
| Stratum B (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b | EXPERIMENTAL | - |
| Stratum C (Phase 2a): Either Dosing Regimen 1 or 2 as finalized in Phase 1b | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| M1774 | DRUG | In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a. |
| Cemiplimab | DRUG | Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason. |
Inclusion Criteria: * Participants who are diagnosed with nsqNSCLC histologically or cytologically confirmed * Participants with Radiologically confirmed/documented disease progression during or after the following systemic therapies (all required): * At most, 1 line of anti-PD-(L)1 therapy for ...
Top 20 of 84 competitors
M1774, also known as tuvusertib, is an investigational small molecule being studied for the treatment of non-squamous Non-Small Cell Lung Cancer (NSCLC). It is currently in Phase 1 clinical development, evaluated in combination with cemiplimab in patients with this condition.
M1774 is a small molecule developed by Merck KGaA. Its specific molecular target is not disclosed in the available information, so its mechanism of action is not described here. The drug is being investigated for its potential role in oncology, specifically in Non-Small Cell Lung Cancer.
M1774 is developed by Merck KGaA, a German multinational pharmaceutical company traded under the ticker MKGAF. The drug is being studied in a Phase 1 clinical trial for Non-Small Cell Lung Cancer, with Merck KGaA as the sponsor.
M1774 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing trial is active but not recruiting participants, and it is evaluating M1774 in combination with cemiplimab for non-squamous Non-Small Cell Lung Cancer.
M1774 is being studied in one active Phase 1 clinical trial with the identifier NCT05882734. This trial, titled 'Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)', enrolls 61 participants across multiple countries including the United States, Belgium, France, Germany, Italy, Japan, South Korea, and Spain.
Yes, M1774 is also known as tuvusertib. The clinical trial NCT05882734 uses the name 'Tuvusertib (M1774)' to refer to the same drug. This investigational small molecule is being developed by Merck KGaA for Non-Small Cell Lung Cancer.